ASCRS 2024: Surgical and pharmaceutical technology updates from Bausch + Lomb


At the 2024 ASCRS meeting, Anthony Wallace details the presentations and educational programmes from Bausch + Lomb

During this year's ASCRS meeting in Boston, Massachusetts, Anthony Wallace, US Surgical vice president and general manager for Bausch + Lomb, detailed new updates from the company. In this Ophthalmology Times interview, he discusses FDA approval of the TENEO excimer laser platform, an expansion of assess for MIEBO and other company updates.

Editor's note: The following transcript has been lightly edited for clarity.

Hi, I'm Anthony Wallace and I lead the surgical business in North America for Bausch and Lomb. We have a number of exciting updates to share with all of you at this year's ASCRS annual meeting. We recently gained FDA approval and launched our TENEO excimer laser platform and the feedback has been really positive. TENEO represents the first new excimer laser approved in the United States in nearly 2 decades, and offers features such as the most advanced eye tracker and the fastest ablation time of any excimer laser on the market. Our surgical team will be sharing updates from our Phase 2 Eyetelligence surgical planning software which include additional functionality, as well as enhanced communication capabilities.

On our IOL portfolio, we recently made available the enVista Aspire with Intermediate Optimised and patients are really benefiting. The feedback has been positive. In fact, more than 500 surgeons have already implanted enVista Aspire since launch. Our manufacturing investments continue to yield improvement for our Apthera IC-8 small aperture lens. We unfortunately had to limit the number of surgeons that could gain availability to Apthera due to our supply constraints, but our investments are really paying off and we anticipate being able to remove all restrictions on inventory ordering by the end of the quarter.

Our pharmaceutical team has expanded access to MIEBO to more than 70 million covered lives throughout the United States. These include payer advancements with United Healthcare, with Optum RX, and with Express Scripts on the commercial side, as well as Cigna on the Medicare Part D side. We continue to work on advancements with payer access throughout the year and we anticipate in 2025 to have significantly improved coverage for MIEBO.

During this year's ASCRS annual meeting, we will have 15 podium presentations, 4 poster presentations, and 3 educational events featuring MIEBO, TENEO, enVista Toric and enVista Aspire, and Apthera IC-8. This is just a snapshot of the updates from Bausch and Lomb. We thank you for your support, and we look forward to sharing more info with you in the near future. Thank you.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.